ARL7 Activators
ARL7 (ADP-Ribosylation Factor-Like 7) is a gene in humans that encodes a member of the ADP-ribosylation factor family of GTP-binding proteins. The ADP-ribosylation factors (ARFs) and ARF-like (ARL) proteins are part of the larger Ras superfamily of small GTPases. These proteins are key regulators of a variety of cellular processes, including vesicular trafficking, cytoskeletal dynamics, and lipid metabolism.ARL7 specifically is classified as an ARL protein and is involved in intracellular trafficking pathways. It plays a role in the transport of proteins and lipids between various cellular compartments. The exact function of ARL7 is not as extensively studied as some other members of the ARF/ARL family, but it is known to be involved in the regulation of endosome-to-Golgi transport. This is crucial for the proper functioning and distribution of proteins and lipids within the cell, affecting various cellular activities and overall cell health.
Like other GTPases, ARL7 cycles between an active GTP-bound state and an inactive GDP-bound state. This cycle is regulated by specific guanine nucleotide exchange factors (GEFs) that promote the exchange of GDP for GTP, and GTPase-activating proteins (GAPs) that stimulate the hydrolysis of GTP to GDP.Mutations or dysregulation of ARL7 and other similar GTPases contribute to various diseases, including cancer and neurodegenerative disorders, although the specific implications of ARL7 in these conditions are not as clearly defined as in some of its more studied counterparts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
As a specific Golgi disruptor, Golgicide A might indirectly affect ARL7 by targeting Golgi dynamics. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As a PI3K inhibitor, Wortmannin can indirectly affect ARL7 through phosphoinositide signaling pathways. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole, a microtubule disruptor, may influence ARL7 activity by altering cellular trafficking. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
By disrupting actin filaments, Cytochalasin D can indirectly impact ARL7's role in cellular processes. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
As a CDC42 inhibitor, ML141 can indirectly influence ARL7 by modulating the Rho family GTPases. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of MEK, PD98059 might indirectly impact ARL7 function via the MAPK signaling pathway. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride can affect GTPase signaling pathways, potentially influencing ARL7. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin might indirectly affect ARL7 through key signaling pathways. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449, a Gsα subunit inhibitor, could indirectly influence ARL7 by affecting G protein-coupled receptor signaling. | ||||||